Page 17 - Read Online

Haydu et al. J Cancer Metastasis Treat 2021;7:36 https://dx.doi.org/10.20517/2394-4722.2021.39 Page 13 of 14

21. Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene Ciloleucel in the non-trial setting: outcomes and correlates of response,
resistance, and toxicity. J Clin Oncol 2020;38:3095-106. DOI PubMed PMC
22. Jaglowski S, Hu ZH, Zhang Y, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-
cell lymphoma (DLBCL): real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
cellular therapy (CT) registry. Blood 2019;134:766. DOI
23. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care Axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma:
results from the US lymphoma CAR T consortium. J Clin Oncol 2020;38:3119-28. DOI PubMed PMC
24. Pasquini MC, Locke FL, Herrera AF, et al. Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell
therapy, axicabtagene ciloleucel (axi-cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood
2019;134:764. DOI
25. Palomba ML, Gordon LI, Siddiqi T, et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma
receiving lisocabtagene maraleucel in transcend NHL 001. Blood 2020;136:10-1.
26. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med
2017;377:2545-54. DOI PubMed PMC
27. Hirayama AV, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell
immunotherapy. Blood 2019;134:636-40. DOI PubMed PMC
28. Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-
modified T-cell therapy. Blood 2017;130:2295-306. DOI PubMed PMC
29. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity
associated with immune effector cells. Biol Blood Marrow Transplant 2019;25:625-38. DOI PubMed
30. Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin
Invest 2016;126:2123-38. DOI PubMed PMC
31. Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in
patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018;8:958-71. DOI PubMed PMC
32. Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive
immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7:1404-19. DOI PubMed PMC
33. Nellan A, McCully CML, Cruz Garcia R, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to
intravenous administration in rhesus macaques. Blood 2018;132:662-6. DOI PubMed PMC
34. Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of
B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J
Clin Oncol 2016;34:1112-21. DOI PubMed PMC
35. Oluwole OO, Bishop MR, Gisselbrecht C, et al. ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus
standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). J Clin Oncol
2018;36:TPS7585. DOI
36. Westin J, Bishop M, Flinn I, et al. BELINDA: a phase 3 study evaluating the safety and efficacy of tisagenlecleucel versus standard of
care in adult patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk
2019;19:S270-1. DOI
37. Neelapu SS, Dickinson M, Ulrickson ML, et al. Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (axi-cel) as
first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Blood 2020;136:49.
38. Le Gouill S, Ghesquieres H, Oberic L, et al. Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3
study by LYSA. Blood 2021;137:2307-20. DOI PubMed
39. Fowler NH, Dickinson M, Dreyling M, et al. Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular
lymphoma: interim analysis of the phase 2 Elara trial. Blood 2020;136:1-3.
40. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell
malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol
2015;33:540-9. DOI PubMed PMC
41. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory
chronic lymphocytic leukemia. Sci Transl Med 2015;7:303ra139. DOI PubMed PMC
42. Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific
chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol 2017;35:3010-20. DOI PubMed PMC
43. Siddiqi T, Soumerai JD, Dorritie KA, et al. Updated follow-up of patients with relapsed/refractory chronic lymphocytic leukemia/small
lymphocytic lymphoma treated with lisocabtagene maraleucel in the phase 1 monotherapy cohort of transcend CLL 004, including
high-risk and ibrutinib-treated patients. Blood 2020;136:40-1.
44. Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.
Ther Adv Hematol 2019;10:2040620719841581. DOI PubMed PMC
45. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of
relapsed/refractory DLBCL with variable CD30 expression. Blood 2015;125:1394-402. DOI PubMed
46. Goy A, Ramchandren R, Ghosh N, et al. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-
germinal center B-cell-like DLBCL. Blood 2019;134:1024-36. DOI PubMed PMC
47. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol
2020;38:155-65. DOI PubMed PMC